Reuters logo
BRIEF-European Commission grants new indication for Soliris
August 21, 2017 / 2:46 PM / a month ago

BRIEF-European Commission grants new indication for Soliris

Aug 21 (Reuters) - Alexion Pharmaceuticals Inc :

* European Commission grants new indication for Soliris® (Eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG)

* EC based approval of extended indication for Soliris on comprehensive clinical data from phase 3 regain study (MG-301)

* EC approved extension of indication for Soliris(Eculizumab) to include treatment of refractory generalized myasthenia gravis Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below